GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OBI Pharma Inc (ROCO:4174) » Definitions » Net Income Including Noncontrolling Interests

OBI Pharma (ROCO:4174) Net Income Including Noncontrolling Interests : NT$-2,475.61 Mil (TTM As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is OBI Pharma Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

OBI Pharma's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2025 was NT$-550.12 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 was NT$-2,475.61 Mil.

OBI Pharma Net Income Including Noncontrolling Interests Historical Data

The historical data trend for OBI Pharma's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OBI Pharma Net Income Including Noncontrolling Interests Chart

OBI Pharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,489.90 -1,717.89 -1,899.32 -1,265.96 -2,492.65

OBI Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -567.16 -589.08 -561.80 -774.61 -550.12

OBI Pharma Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-2,475.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OBI Pharma Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of OBI Pharma's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

OBI Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OBI Pharma Inc (ROCO:4174) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
ROCO:6586 ROCO:6976 ROCO:4726 TPE:4142 TPE:6949 ROCO:6696 ROCO:4157 ROCO:7832 ROCO:7759 ROCO:4167 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
Zhongxiao E Road, 6th Floor, No. 508, Section 7, Nangang District, Taipei, TWN, 115
Website
https://www.obipharma.com
OBI Pharma Inc is engaged in new drugs research of novel cancer therapeutic agents for patients with unmet medical needs. The company has four reportable segments, which are anti-cancer new drug segment, bispecific monoclonal antibody new drug segment, botulinum toxin new drug segment and CDMO segment.

OBI Pharma Headlines

No Headlines